Report on the Drug Situation 2010 - Bundesministerium fÃ¼r ...

More documents

Recommendations

Info

In the EMCDDA working group on cohort mortality, an analysis of directly drug-related mortality of people undergoing opioid substitution treatment was carried out in 2010. Figure 6.3 Directly drug-related deaths per 1 000 person years of men, women and total number, of people entering OST for the first time in the period between 1 January 2000 and 31 December 2008 8 7 6 5 4 3 6.40 5.60 2 3.50 1 0 Men Women Total Note: The black lines refer to the width of the 95% confidence intervals. Source: data analysis and representation by GÖG/ÖBIG For this purpose, the data from the substitution registry and the statistics of drugrelated deaths were linked after they had been pseudonymised 30 . The analysis relates to those persons who between 1 January 2000 and 31 December2008 entered opioid substitution treatment for the first time in life. 30 Pseudonymisation means that personal data such as name, date of birth, etc., are replaced by an identifier that cannot be traced back. In this way it is possible to see which data refer to one and the same person without permitting an identification of concrete persons. 62 © GÖG/ÖBIG, <strong>Report</strong> on the Drug Situation 2010
This applies to a total number of 9 716 people. The sum of years in which these people have been registered in the observation period, results in a total of 35 497 person years 31 . The average age at entering the cohort (= beginning of first treatment) was 27.3 years, and the share of women was 26%. A total of 200 people out of the group of 9 716 patients died of an overdose in the period between 2000 and 2008. The mortality rate was 5.6 (95% confidence interval: 4.9 to 6.5) deaths per 1 000 person years (see ST 18). An interesting aspect is that the mortality rate regarding directly drug-related deaths is significantly lower among women than among men (see Figure 6.3 and Chapter 5.3). One has to take into account, however, that this analysis exclusively relates to overdoses and thus to directly drug-related deaths. It does not permit conclusions as to total mortality of people in OST (e.g., death because of diseases associated with drug use, etc.; GÖG/ÖBIG, under preparation). 31 The term person year refers to the time during which a person is observed in the context of a cohort study. For instance, in the cohort in question, any person entering OST on 1 January 2000 contributes nine person years (except people who died before 31 December 2008). Any person entering OST on 1 January 2001 contributes eight person years, etc. For instance, if a person enters OST on 1 January 2002 and dies on 30 June 2002, they account for half a person year. In many mortality cohort analyses, the mortality rate is expressed as deaths per 1 000 person years. Chapter 6 / Health Correlates and Consequences 63
Page 1:
Report on the Drug
Page 4 and 5:
ISBN-13 978-3-85159-153-8 Owner, ed
Page 6 and 7:
Prevention The trend towards drawin
Page 8 and 9:
hardly known. This makes it impossi
Page 10 and 11:
6 Health Correlates and Consequence
Page 12 and 13:
Tables and Figures Tables Table 6.1
Page 14 and 15:
Table A22 Table A23 Table A24 Table
Page 16 and 17:
Figure 9.1 Figure 9.2 Figure 9.3 Fi
Page 19:
Part A New Developments and Trends
Page 22 and 23:
The amendment to the Narcotic Drugs
Page 24 and 25:
deaths (see GÖG/ÖBIG 2009b) conti
Page 26 and 27:
In the reporting period, no new dev
Page 28 and 29: 2.1 Drug use in the general populat
Page 30 and 31: The quitting rate 3 is considerably
Page 32 and 33: Figure 2.2 Experience of cannabis u
Page 34 and 35: described on the individual website
Page 36 and 37: ehaviour is elevated for children i
Page 38 and 39: theme of the Gesunde Gemeinden (hea
Page 40 and 41: party scenes are relevant settings.
Page 42 and 43: support if needed. The project is i
Page 44 and 45: approximations and have to be inter
Page 46 and 47: Figure 4.2 2-sample CRC estimates w
Page 48 and 49: 5 Drug-related Treatment: Treatment
Page 50 and 51: 2010, now 50 doctors are entitled t
Page 52 and 53: patients for inpatient treatment al
Page 54 and 55: Map 5.2 Specialised providers of ou
Page 56 and 57: cooperation structures linking the
Page 58 and 59: events are organised, and on the ot
Page 60 and 61: 5.3 Characteristics of treated clie
Page 62 and 63: play the most important role in the
Page 64 and 65: existing treatment system who do no
Page 66 and 67: 5.4 Trends of clients in treatment
Page 68 and 69: Figure 5.7 First substitution treat
Page 70 and 71: 6 Health Correlates and Consequence
Page 72 and 73: Table 6.1 Data on hepatitis B, hepa
Page 74 and 75: ange from affective disorders (e.g.
Page 76 and 77: Figure 6.1 Share of directly drug-r
Page 80 and 81: 7 Responses to Health Correlates an
Page 82 and 83: 7.2 Prevention and treatment of dru
Page 84 and 85: distribution of condoms) is provide
Page 86 and 87: information on the risks of additio
Page 88 and 89: While smaller shares of women state
Page 90 and 91: Map 8.1 Specialised providers of in
Page 92 and 93: The Lighthouse housing project of M
Page 94 and 95: empowerment that had been aimed at,
Page 96 and 97: handling of drugs: Section 27 of th
Page 98 and 99: also shows regarding prison sentenc
Page 100 and 101: Stadtpark, and Westbahnhof station.
Page 102 and 103: mation on final convictions because
Page 104 and 105: practitioners and psychiatrists). I
Page 106 and 107: 10 Drug Markets The substance most
Page 108 and 109: head shop in Graz (Styria) in Augus
Page 110 and 111: (from 2005 to 2008, the correspondi
Page 113: Part B Selected Issues
Page 116 and 117: national quality standards for medi
Page 118 and 119: Also, both at federal and provincia
Page 120 and 121: Table 11.1, continued Title and yea
Page 122 and 123: Plans for new guidelines and standa
Page 124 and 125: 12 Cost of Drug-related Treatment T
Page 126 and 127: centres so far (Schweizer Haus Hade
Page 128 and 129:
greatest percentage of the respecti
Page 130 and 131:
(e.g., days of hospital stay becaus
Page 133 and 134:
Bibliography APA 2010. AIDS 2010. W
Page 135 and 136:
EMCDDA 2000. Treatment demand indic
Page 137 and 138:
Haas, S. (2005). Problembewusste Fr
Page 139 and 140:
Pont, J.; Wool, R. (2006). Ein Leit
Page 141 and 142:
VIVID 2010. Jahresbericht 2009. VIV
Page 143 and 144:
Personal Communications (alphabetic
Page 145 and 146:
Caritas Marienambulanz. Drug relate
Page 147 and 148:
Low threshold service Ganslwirt (Ve
Page 149 and 150:
Viennese pilot project “Pregnancy
Page 151 and 152:
Lower Austria: Fachstelle für Such
Page 153 and 154:
Caritas Innsbruck http://www.carita
Page 155 and 156:
Otto-Wagner-Spital — Drogeninstit
Page 157:
Annex A. Tables, Map B. List of Abb
Page 161 and 162:
Table A1 Overview of selected gener
Page 163 and 164:
Table A2, continued Study (author(s
Page 165 and 166:
Table A5 Number of directly drug-re
Page 167 and 168:
Table A7 Distribution of directly d
Page 169 and 170:
Table A11 Distribution of reports o
Page 171 and 172:
Table A15 Final convictions under t
Page 173 and 174:
Table A18 Seizures of narcotic drug
Page 175 and 176:
Table A22 Persons starting drug tre
Page 177 and 178:
Page 179 and 180:
Page 181 and 182:
Table A29 Current health problems o
Page 183 and 184:
The programme plus is implemented i
Page 185 and 186:
Proven regional interventions run f
Page 187 and 188:
Table A34 Austrian population stati
Page 189:
Annex B List of Abbreviations
Page 192 and 193:
HCV HCV-Ab HCV-RNA HIV ICD-10 IFES
Page 195 and 196:
List of Standard Tables of 2010 and
Page 197:
© Gesundheit Österreich GmbH Stub
show all

Report on the Drug Situation 2010 - Bundesministerium fÃ¼r ...

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?